Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Metabolism of [14C]Navlimetostat in Healthy Female Participants
NCT07777133Phase 1Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 2
01
Overview
Phase 1 trial of navlimetostat (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 14 days, Time of maximum observed plasma concentration up to 14 days and 18 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
navlimetostat
Beyond the preview
Go deeper on NCT07777133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07777133.